Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression.

Shoaib UgradarLu ShiYao WangTunde MesterHuasheng YangRaymond S Douglas

Published in: Eye (London, England) (2020)

Our findings demonstrate for the first time, that teprotumumab, a blocking antibody to the IGF-1R reduces proptosis in a series of patients with non-inflammatory TED. Overexpression of the IGF-1R in orbital tissue from patients with non-inflammatory disease compared to controls may be an important consideration for effect.

Keyphrases

binding protein
oxidative stress
pi k akt
poor prognosis
growth hormone
cell proliferation
transcription factor
signaling pathway
long non coding rna